Dr Carraway on the Importance of NGS in Relapsed/Refractory AML
Hetty E. Carraway, MD, MBA, discusses the importance of testing for targetable mutations in patients with relapsed/refractory acute myeloid leukemia.
Source: onclive.com
Hematologic Oncology News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hematologic Oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hematologic Oncology Today - Breaking & Trending Today
Uproleselan Plus Chemotherapy Misses Phase 3 Trial OS End Point in R/R AML
Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.
Source: onclive.com
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward
Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.
Source: onclive.com
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Source: onclive.com
SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease
SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.
Source: onclive.com